FI54916C - Foerfarande foer framstaellning av terapeutiskt verksamma n-substituerade 2-pyrrolidoner - Google Patents

Foerfarande foer framstaellning av terapeutiskt verksamma n-substituerade 2-pyrrolidoner

Info

Publication number
FI54916C
FI54916C FI383/71A FI38371A FI54916C FI 54916 C FI54916 C FI 54916C FI 383/71 A FI383/71 A FI 383/71A FI 38371 A FI38371 A FI 38371A FI 54916 C FI54916 C FI 54916C
Authority
FI
Finland
Prior art keywords
pyrrolidoner
nutritional
substitute
framework
therapeutic treatment
Prior art date
Application number
FI383/71A
Other languages
English (en)
Other versions
FI54916B (fi
Inventor
Joseph Honore Lucien M Strubbe
Raymond Armand Linz
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of FI54916B publication Critical patent/FI54916B/fi
Application granted granted Critical
Publication of FI54916C publication Critical patent/FI54916C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI383/71A 1970-02-13 1971-02-10 Foerfarande foer framstaellning av terapeutiskt verksamma n-substituerade 2-pyrrolidoner FI54916C (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB697870A GB1309692A (en) 1970-02-13 1970-02-13 N-substituted lactams

Publications (2)

Publication Number Publication Date
FI54916B FI54916B (fi) 1978-12-29
FI54916C true FI54916C (fi) 1979-04-10

Family

ID=9824325

Family Applications (1)

Application Number Title Priority Date Filing Date
FI383/71A FI54916C (fi) 1970-02-13 1971-02-10 Foerfarande foer framstaellning av terapeutiskt verksamma n-substituerade 2-pyrrolidoner

Country Status (15)

Country Link
JP (2) JPS535301B1 (fi)
BE (1) BE762728R (fi)
CH (1) CH530395A (fi)
CS (2) CS167911B2 (fi)
DE (1) DE2106418C2 (fi)
DK (1) DK137451B (fi)
ES (1) ES388135A2 (fi)
FI (1) FI54916C (fi)
FR (1) FR2081508B2 (fi)
GB (1) GB1309692A (fi)
MY (1) MY7400072A (fi)
NL (1) NL168830C (fi)
SU (2) SU508186A3 (fi)
YU (2) YU34876B (fi)
ZA (1) ZA71877B (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1045043B (it) * 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
GB1583871A (en) * 1976-10-19 1981-02-04 Ucb Sa Anti-aggregants
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
DE2960194D1 (en) 1978-05-08 1981-04-16 Ucb Sa Lactam-n-acetic acids, their amides, process for their preparation and therapeutic compositions containing them
IT1141287B (it) * 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
EP0089900B1 (en) * 1982-03-24 1985-12-27 Prodes S.A. New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
DE3420193A1 (de) * 1984-05-30 1985-12-05 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel
US4804400A (en) * 1986-09-12 1989-02-14 Ciba-Geigy Corporation N-phenyl-maleimides and herbicidal and plant growth regulating methods of use thereof
GB8827389D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
TW544311B (en) * 1998-08-06 2003-08-01 Daiichi Seiyaku Co Therapeutic or preventive agent for intractable epilepsies
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
ATE410412T1 (de) 2001-08-10 2008-10-15 Ucb Pharma Sa Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
CA2461961A1 (en) * 2001-10-08 2003-04-17 Ucb, S.A. Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
EP1517893A2 (en) 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
US7531673B2 (en) 2004-02-18 2009-05-12 Dr. Reddy's Laboratories Limited Preparation of amino acid amides
CA2488325C (en) 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
US20080146819A1 (en) * 2005-03-10 2008-06-19 Rubamin Limited Process for Preparing Levetiracetam
CA2610695A1 (en) 2005-06-01 2006-12-07 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
CN102227217A (zh) 2008-10-16 2011-10-26 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
CN104059010A (zh) * 2014-06-12 2014-09-24 浙江华海药业股份有限公司 一种制备2-(2-氧代吡咯烷-1-基)-丁酸酯的方法
CN106591179B (zh) * 2016-12-05 2018-07-03 长兴制药股份有限公司 甲基包囊菌及其在选择性拆分制备(S)-α-乙基-2-氧-1-吡咯烷乙酸盐上的应用
RU2663899C1 (ru) * 2017-07-19 2018-08-13 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Способ получения 1-карбамоилметил-4-фенил-2-пирролидона
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) * 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams

Also Published As

Publication number Publication date
ES388135A2 (es) 1973-05-01
JPS53130656A (en) 1978-11-14
DK137451B (da) 1978-03-06
FI54916B (fi) 1978-12-29
DE2106418C2 (de) 1983-12-22
DE2106418A1 (de) 1971-08-19
FR2081508B2 (fi) 1975-06-06
CS167911B2 (fi) 1976-05-28
DK137451C (fi) 1978-07-24
SU508186A3 (ru) 1976-03-25
NL7101697A (fi) 1971-08-17
CH530395A (fr) 1972-11-15
JPS535301B1 (fi) 1978-02-25
SU508185A3 (ru) 1976-03-25
ZA71877B (en) 1971-10-27
NL168830B (nl) 1981-12-16
GB1309692A (en) 1973-03-14
BE762728R (fr) 1971-08-10
JPS5420491B2 (fi) 1979-07-23
NL168830C (nl) 1982-05-17
YU30671A (en) 1979-10-31
YU144578A (en) 1982-10-31
MY7400072A (en) 1974-12-31
YU34876B (en) 1980-04-30
FR2081508A2 (fi) 1971-12-03
CS167912B2 (fi) 1976-05-28

Similar Documents

Publication Publication Date Title
FI54916B (fi) Foerfarande foer framstaellning av terapeutiskt verksamma n-substituerade 2-pyrrolidoner
SE387861B (sv) Apparat for forangningsbehandling av vetskor
SE393381B (sv) Analogiforfarande for framstellning av 8-azapurin - 6 - onderivat
FI54301C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara kinazolinderivat
SE400083B (sv) Forfarande for framstellning av humant karcinoembryonalt antigen
SE390304B (sv) Analogiforfarande for framstellning av 4-hydroxi-5-etyl-6-fonylpyrimidin
SE384529B (sv) Apparat for behandling av djurhudar eller liknande
FI55184B (fi) Foerfarande foer framstaellning av terapeutiskt verksamma fenyl-2-pyrrolidinoner samt deras isomerer
SE388422B (sv) Forfarande for reduktion av theabin
BE776863A (fr) Redistribution des alkylhydrosilanes
FI54100C (fi) Foerfarande foer framstaellning av terapeutiskt vaerdefulla tricykliska foereningar
DOP1971001881A (es) Tratamiento de dientes
FI54104C (fi) Foerfarande foer framstaellning av terapeutiskt verksamma pyrrolidinonfoereningar
FI54602C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 6-amidinopenicillansyraderivat
FI55988C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara o-acylfenoletanolaminer
FI53967B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara bensobicykloalkanaminer
FI55503B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara pyrimidinonderivat
SE384142B (sv) Behandlingskammare
FI53700C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara diaminopropiofenonderivat
FI53819C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara n-lysergyl-3-aminopyridiner
FI55338C (fi) Foerfarande foer framstaellning av terapeutiskt verksamma n-metyl-imidazoler
ZA716294B (en) Treatment of leather
SE382051B (sv) Forfarande for framstellning av 3-sulfonamid-4-hydroxifenyl-2-piperidylkarbinoler
FI56171B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva asylerade piperidin-, tetrahydropyridin- och pyridinderivat
FI56179C (fi) Foerfarande foer framstaellning av terapeutiskt verksamma imidazolderivat